Beacon Therapeutics
Latest round
- Series C
Last raised
- Dec 2025
Total raised
- $365M
Investors
- 7
About Beacon Therapeutics
Based in London, UK, and founded in 2023, Beacon Therapeutics Limited, formerly known as Alliance Holdco Limited, operates as an ophthalmic gene therapy company that develops treatments for eye diseases. The company works on the development of gene therapy to restore and improve the vision of patients suffering from various prevalent and rare retinal diseases that lead to blindness. Beacon Therapeutics combines a late-stage development candidate for X-linked retinitis pigmentosa (XLRP) with two innovative preclinical programs targeting prevalent and rare blinding diseases. Their gene therapy approach involves modifying a patient's cells by introducing a functional copy of the mutated gene responsible for the disease, allowing the body to produce the necessary proteins to treat or prevent the genetic condition. As of June 2023, Beacon Therapeutics has a diverse pipeline, including a Phase 2 clinical trial for their lead development candidate, AGTC-501, designed to treat XLRP. Additionally, the firm is developing preclinical programs for dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), both of which are inherited retinal diseases.
Who invested in Beacon Therapeutics
7 investors across 3 rounds
See all investors in Beacon Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beacon Therapeutics
Who invested in Beacon Therapeutics?
Beacon Therapeutics has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beacon Therapeutics raised?
Beacon Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Beacon Therapeutics last raise money?
Beacon Therapeutics's most recent round on record is a Series C, in Dec 2025.
What does Beacon Therapeutics do?
Based in London, UK, and founded in 2023, Beacon Therapeutics Limited, formerly known as Alliance Holdco Limited, operates as an ophthalmic gene therapy company that develops treatments for eye diseases.
Where is Beacon Therapeutics headquartered?
Beacon Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Beacon Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Beacon Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Beacon Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.